| Name | Title | Contact Details |
|---|
Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to concentrate on high growth potential markets where there are visible, distinct needs recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Every day` 119`000 compassionate caregivers serve patients and communities through Providence St. Joseph Health` a national` Catholic` not-for-profit health system` driven by a belief that health is a human right. Rooted in the founding missions of the Sisters of Providence and the Sisters of St. Joseph of Orange` courageous women ahead of their time who brought health care and other social services to the American West when it was still a rugged` untamed frontier` we share a singular commitment to improve the health of all. From our earliest days` we’ve met new challenges by pioneering new solutions. Today` with 51 hospitals` 829 clinics and a comprehensive range of services` we strive to meet the needs of communities across Alaska` California` Montana` New Mexico` Oregon` Texas and Washington through a diverse family of Catholic` other faith-based and mission-driven secular organizations. Now` as we face a new frontier—a changing health care landscape—we draw upon their pioneering and compassionate spirit to plan for the next century of health for a better world` especially for the poor and vulnerable. If you need treatment` please visit www.providence.org to locate a health care provider.
DVM Resources is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VitaPath Genetics is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.